44 results about "Carcinoma bladder" patented technology

The present invention relates to a method for detecting c.-124 C>T and c.-146 C>T mutations in the Htert gene promoter. The method uses reaction compositions that comprise amplification primers and genotyping probes. Another aspect of this invention relates to the primers and probes used to implement the aforementioned method, with sequences, identified as SEQ ID no.1 to SEQ ID no.6, that displayhigh specificity for these mutations, and to the compositions containing these primers and probes. The present invention further relates to a kit comprising the above-mentioned compositions for detecting c.-124 C>T and c.-146 C>T mutations in the Htert gene promoter by carrying out the method according to the present invention. The method, gene sequences, compositions and kit of the present invention can be advantageously used for detecting trace amounts of c.-124 C>T and c.-146 C>T mutations in biological samples, due to their high sensitivity and specificity for such mutations. The present invention can thus be applied in early detection, identification, detection of recurrence or prediction and monitoring of diseases associated with this type of mutations, such as bladder carcinomas, thyroid carcinomas, squamous cell carcinomas, basal cell carcinomas, melanomas, gliomas and hepatocellular carcinomas, inter alia, and ultimately provide the basis for defining a suitable treatment. Thus, the present invention pertains to the technical fields of medicine, pharmaceutics, molecular biology, biochemistry, human genetics and the like.

The present invention provides a human low-invasive bladder cancer cell line, specifically, a new human low-invasive bladder cancer cell line CH‑1, which was preserved in the China Center for Type Culture Collection on August 26, 2013 ( CCTCC, China, Wuhan), the deposit number is CGMCC No.C2013128. The cell line of the present invention has stable cell morphology and passage characteristics, good tumorigenicity, and the cell line does not appear distant metastasis, can be used for the establishment of animal models, and can be used in combination with multi-organ metastatic bladder cancer cell lines for screening Drugs for different properties of bladder cancer, and for screening genes related to metastasis.

The invention relates to a group six dim carbocyclic ring azoles nucleoside analogues and their acceptable pharmaceutical compounds and their preparation methods and the application as antiviral and antineoplastic agents.The described compounds have varying degrees of inhibition effects on the human immunodeficiency virus replication and the replication of herpes virus; have varying degrees of inhibition on human lung cancer cell lines and human bladder cancer cell lines.

The invention provides an immune-enhancing antineoplastic collagen composition as well as a preparation method and an application thereof. The composition is characterized by consisting of antineoplastic factors, collagen, polysaccharide substances and active factors. The composition is applicable to, but not limited in, cells for treating breast cancer, colorectal cancer, ovarian cancer, pancreatic cancer, prostatic cancer, bladder cancer, melanoma, lung cancer, stomach cancer, liver cancer, head and neck squamous cell carcinoma, carcinoma of uterine cervix, renal cell carcinoma, thyroid cancer, acute myeloid leukemia, myeloma, esophageal squamous cancer, lymphoma and the like.

The present invention discloses a DC-CIK co-cultured cell, a preparation method thereof, a sensitizing antigen and an application thereof. The DC-CIK co-cultured cell is prepared by using separated mononuclear cells to be respectively induced and cultured into DC cells and CIK cells, wherein the DC cells are induced and stimulated by adding a self-constructed polypeptide sensitizing antigen whichis proven to be widely expressed in various tumor cells during a culture process, which can improve tumor killing effects. The DC-CIK co-cultured cell cultured by the method can have a very good killing effect on a variety of the tumor cells. Besides, the cultured DC-CIK cells have high activity and strong amplification ability, releases many cytokines of IFN-gamma, etc., and is strong in lethality. The co-cultured cell can be widely used in treatment of various cancers, including kidney cancers, prostate cancers, breast cancers, bladder cancers, melanoma, colon cancers, ovarian cancers, bonecancers, lung cancers, neuroblastoma, etc., and is wide in adaptive surfaces.

The invention discloses application of argyreia aceta alkali in biological medicines. The whole herb of argyreia aceta has medicinal value, and argyreia aceta is widely distributed in many places of Guangxi, such as Guigang, Yulin, Fangcheng Gang and Wuming, and is used as a traditional Chinese medicine for treating acute and chronic bronchitis, tuberculosis, liver cirrhosis, nephritis edema, sores and furuncles, acute mastitis, skin eczema, traumatic bleeding and other symptoms. The argyreia aceta alkali is a chemical component separated from argyreia aceta. According to the invention, through the tests for the proliferation inhibition effect of the argyreia aceta alkali on human lung adenocarcinoma cell H2228, human bladder cancer cell T24, human hepatoma carcinoma cell SMMC-7721, humanbreast cancer cell MCF-7, human gastric carcinoma cell MGC-803 and human oral squamous cell carcinoma Tca8113, the argyreia aceta alkali is found to have an excellent inhibiting effect on human bladder cancer cell T24 and human oral squamous cell carcinoma Tca8113 and has no obvious inhibiting effect on other tested tumor cells, so that the argyreia aceta alkali can be used for preparing drugs fortreating bladder cancer or oral squamous cell carcinoma.

The present invention provides a kind of no-cell Calmette-Guerin bacillus preparation, and medicine composition or mucosa immune regulator including the preparation. The no-cell Calmette-Guerin bacillus preparation is prepared through crushing and cracking Calmette-Guerin bacillus in a homogenating crushing process or ultrasonic crushing process. The preparation can strengthen immunological function of normal body, promote restoring of immunological function in hypoimmunity body and inhibit excessive immune response in hyperimmunity body, and has bidirectional immunological regulation. The preparation has obvious tumor inhibiting effect, can prevent cancers, and is one kind of safe and effective mucosa immune regulator.

The present invention relates to a novel regulatory T cell protein. The protein, named PD‑L3ORVISTA, resembles members of the PD‑L1 family and represents a novel and structurally distinct Ig superfamily inhibitory ligand whose ectodomain has the same identity as the B7 family ligand PD‑L1. source. This molecule is called PD‑L3OR VISTA or V-domain immunoglobulin inhibitor of T-cell activation (VISTA). The expression of VISTA is mainly localized in the hematopoietic compartment and is highly regulated on bone marrow APCs and T cells. Therapeutic intervention of the VISTA inhibitory pathway suggests a new approach to modulate T cell-mediated immunity for the treatment of various cancers such as ovarian, bladder and melanoma. Additionally, VISTA proteins, particularly multimeric VISTA proteins and antibodies are useful for suppressing T cell immunity in autoimmune diseases, allergies, infections and inflammatory disorders such as multiple sclerosis and joint disorders such as RA.